EichorEICHOR
Study identifier: NCT06518317 Synced from ClinicalTrials.gov · August 08, 2026
● Study status: RecruitingSOLOTAVI

Short Versus Long Antiplatelet Therapy After TAVI

Condition: Transcatheter Aortic Valve Replacement  ·  Sponsor: University Hospital, Caen

PhasePhase 3
Planned participants1400
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNoCheck eligibility criteria ↓
WhereCaen, France

Interested? Contact the study team ↓

For sponsors, CROs & site teams
Professional view of this study — listed sites, countries and recruiting context from the public registry. Everything below is written for patients and caregivers.See where this study is running →

About this study

The goal of this clinical trial is to learn if reducing the duration of treatment by aspirin to 3 months (short treatment regimen) after percutaneous aortic valve replacement is as safe and efficient as the routine lifetime treatment by aspirin (standard treatment regimen). The main questions it aims to answer are: Does the reduction of the duration of aspirin reduces rates of bleeding without increasing the risk of cardiovascular events. Researchers will compare a short treatment by aspirin (3 months) to a long treatment by aspirin (12 months) after percutaneous replacement of the aortic valve. Participants will: Take aspirin for 3 months in one group or 12 months in another group Be contacted by phone or visit the clinic at 3, 4, 6, 8, 10 and 12 months after hospital discharge Keep a diary of any bleeding or cardiovascular events occurring during the study period

This description comes directly from the study's public registry record.

Talk to the study team

Farzin Beygui, MD,PhD  ·  +33231063350  ·  beygui-f@chu-caen.fr

Clemence Thomadesso, PhD  ·  +33231065386  ·  tomadesso-c@chu-caen.fr

There is no obligation to join — the study team can answer your questions about taking part.

Always discuss trial participation with your own doctor first.

Full eligibility criteria (exactly as the study team wrote them)

Inclusion Criteria: * Age ≥ 18 * Male or, post-menopausal -with no menses for 12 months without an alternative medical cause- or permanently sterilized -hystercetomy, bilateral salpingectomy or bilateral oophorectomy- female * Successful transfemoral TAVI for symptomatic aortic stenosis as defined by VARC-33 * Successful access, delivery of the device, and retrieval of the delivery system * Correct positioning of a single prosthetic heart valve into the proper anatomical location * Freedom from surgery or intervention related to the device (excluding permanent pacemaker) or to a major vascular or access-related, or cardiac structural complication * Written informed consent * Social security affiliated * French speaking Exclusion Criteria: * Un-successful TAVI defined by the absence of any of the above-mentioned criteria defining successful TAVI3 * Alternative non-femoral-approach TAVI: apical, direct trans-aortic, subclavian, axillary or carotid approaches * TAVI for other indications than aortic stenosis (pure aortic regurgitation) * Valve in valve TAVI * Any indication for long term antiplatelet therapy: (e.g. coronary artery disease, cerebrovascular disease, peripheral arterial disease…) at any time prior to randomization * Any indication for oral anticoagulation: (e.g. atrial fibrillation, deep vein thrombosis, pulmonary embolism, ventricular thrombus…) at any time prior to randomization * Patients on long term antiplatelet or anticoagulant therapy prior to TAVI for any other indication than TAVI * Any contraindication to long term antiplatelet therapy (e.g. allergy or intolerance to aspirin, major bleeding, high bleeding risk, thrombocytopenia \< 50 000, major haemostasis disorder…) * Women of childbearing potential: non menopaused -with no menses for 12 months without an alternative medical cause- and not permanently sterilized -hystercetomy, bilateral salpingectomy or bilateral oophorectomy- * Adult with protective measures (tutorship, curatorship) * Patients considered as vulnerable by the investigators because of medical, psychological or social conditions: * Patients with known or discovered severe cognitive impairment * Patients with treated or untreated severe psychological or psychiatric conditions * Patients with uncorrected severe hearing or visual handicap * Patients with addictive alcohol, drug or substance abuse * Patients with protective measures (guardianship, tutorship, curatorship) * Any other condition considered by the investigators as not warranting informed consent

Reproduced word-for-word from the public registry record — the study team can answer questions about it.

Locations (1)

Caen University HospitalCaen, FranceRecruiting

More studies in these areas

This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.

Caen

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Look up another condition
Look up another city
Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →